Distribution of Metastases After Radiotherapy in Relation to Radiation Exposure Fields: Evaluation by F-FDG PET/CT

Overview

Journal Sci Rep

Specialty Science

Date 2024 Nov 30

PMID 39616185

Authors

Jiucen Liang

Wei Li

Rusen Zhang

Wen Li

Peiyin Lin

Hao Nie

Affiliations

Soon will be listed here.

Abstract

To evaluate the distribution of metastases after radiotherapy using F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (F-FDG PET/CT). 67 patients with 501 new metastases revealed by 18F-FDG PET/CT after radiotherapy were included in this retrospective study. The metastases were divided into radiation area (RA) and non-radiation area (NRA), based on their locations inside or outside the radiation exposure field. Patients were divided into two groups based on the comparison of lesions number between RA and NRA: group A (NRA ≤ RA) and group B(NRA > RA). The distribution characteristics of metastases and their relationship with clinical data were analyzed. 67 patients were included in the study. A total of 501 lesions were detected: 122 in RA and 379 in NRA. 28 patients resulted in group A and 39 in group B. Patients with lesion number (LN) ≤ 5 were primarily assigned to Group A (56.1%, 23/41), whereas those with LN > 5 were primarily assigned to Group B (80.8%, 21/26). A statistically significant difference in lesion count was observed between the two groups (χ = 8.809, P = 0.003).Among 19 patients with RA = 0, 17 had LN ≤ 5 and 2 had LN > 5. In contrast, among 25 patients with NRA = 0, 10 had LN ≤ 5 and 15 had LN > 5. A significant difference was noted between patients with RA = 0 and those with NRA = 0 (χ = 4.728, P = 0.030). An notable characteristic in the distribution of metastases following radiotherapy is their tendency to occur outside the irradiation area. This indicated that the radiotherapy exposure area acquires a certain tumor growth inhibitory effect, potentially lasting over time. Based on these observations, there may be potential for developing novel preventive irradiation techniques.

References

Chen G, Cui J, Qian J, Zhu J, Zhao L, Luo B . Rapid Progress in Intelligent Radiotherapy and Future Implementation. Cancer Invest. 2022; 40(5):425-436. DOI: 10.1080/07357907.2022.2044842. View

Lee J, Lee S . Radiomics in Oncological PET/CT: Clinical Applications. Nucl Med Mol Imaging. 2018; 52(3):170-189. PMC: 5995782. DOI: 10.1007/s13139-017-0500-y. View

Le Pechoux C, Al Mohkles H, Dhermain F . [Present role of prophylactic cranial irradiation]. Bull Cancer. 2013; 100(1):35-43. DOI: 10.1684/bdc.2012.1678. View

Dillon M, Barker H, Pedersen M, Hafsi H, Bhide S, Newbold K . Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei. Mol Cancer Ther. 2017; 16(1):25-34. PMC: 5302142. DOI: 10.1158/1535-7163.MCT-16-0239. View

Lara-Vega I, Correa-Lara M, Vega-Lopez A . Effectiveness of radiotherapy and targeted radionuclide therapy for melanoma in preclinical mouse models: A combination treatments overview. Bull Cancer. 2023; 110(9):912-936. DOI: 10.1016/j.bulcan.2023.05.002. View

Abubakar M, Sung H, Bcr D, Guida J, Tang T, Pfeiffer R . Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population. Breast Cancer Res. 2018; 20(1):114. PMC: 6145192. DOI: 10.1186/s13058-018-1033-8. View

Kuonen F, Secondini C, Ruegg C . Molecular pathways: emerging pathways mediating growth, invasion, and metastasis of tumors progressing in an irradiated microenvironment. Clin Cancer Res. 2012; 18(19):5196-202. DOI: 10.1158/1078-0432.CCR-11-1758. View

Adra J, Lundstedt D, Killander F, Holmberg E, Haghanegi M, Kjellen E . Distribution of Locoregional Breast Cancer Recurrence in Relation to Postoperative Radiation Fields and Biological Subtypes. Int J Radiat Oncol Biol Phys. 2019; 105(2):285-295. DOI: 10.1016/j.ijrobp.2019.06.013. View

Carvalho H, Villar R . Radiotherapy and immune response: the systemic effects of a local treatment. Clinics (Sao Paulo). 2018; 73(suppl 1):e557s. PMC: 6257057. DOI: 10.6061/clinics/2018/e557s. View

10.

Zhou X, Liu H, Zheng Y, Han Y, Wang T, Zhang H . Overcoming Radioresistance in Tumor Therapy by Alleviating Hypoxia and Using the HIF-1 Inhibitor. ACS Appl Mater Interfaces. 2020; 12(4):4231-4240. DOI: 10.1021/acsami.9b18633. View

11.

McLaughlin M, Patin E, Pedersen M, Wilkins A, Dillon M, Melcher A . Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020; 20(4):203-217. DOI: 10.1038/s41568-020-0246-1. View

12.

J W, J J B, L D, S A R M, Sh F, S M J M . Abscopal Effect Following Radiation Therapy in Cancer Patients: A New Look from the Immunological Point of View. J Biomed Phys Eng. 2020; 10(4):537-542. PMC: 7416099. DOI: 10.31661/jbpe.v0i0.1066. View

13.

Lhuillier C, Rudqvist N, Yamazaki T, Zhang T, Charpentier M, Galluzzi L . Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. J Clin Invest. 2021; 131(5). PMC: 7919731. DOI: 10.1172/JCI138740. View

14.

Due A, Vogelius I, Aznar M, Bentzen S, Berthelsen A, Korreman S . Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Radiother Oncol. 2014; 111(3):360-5. PMC: 4469149. DOI: 10.1016/j.radonc.2014.06.001. View

15.

Yu Z, Xu C, Song B, Zhang S, Chen C, Li C . Tissue fibrosis induced by radiotherapy: current understanding of the molecular mechanisms, diagnosis and therapeutic advances. J Transl Med. 2023; 21(1):708. PMC: 10563272. DOI: 10.1186/s12967-023-04554-0. View

16.

Ribatti D, Mangialardi G, Vacca A . Stephen Paget and the 'seed and soil' theory of metastatic dissemination. Clin Exp Med. 2006; 6(4):145-9. DOI: 10.1007/s10238-006-0117-4. View

17.

Cliffe H, Patel C, Prestwich R, Scarsbrook A . Radiotherapy response evaluation using FDG PET-CT-established and emerging applications. Br J Radiol. 2016; 90(1071):20160764. PMC: 5601535. DOI: 10.1259/bjr.20160764. View

18.

Israel I, Blass G, Reiners C, Samnick S . Validation of an amino-acid-based radionuclide therapy plus external beam radiotherapy in heterotopic glioblastoma models. Nucl Med Biol. 2011; 38(4):451-60. DOI: 10.1016/j.nucmedbio.2010.12.002. View

19.

Fokas E, Engenhart-Cabillic R, Daniilidis K, Rose F, An H . Metastasis: the seed and soil theory gains identity. Cancer Metastasis Rev. 2007; 26(3-4):705-15. DOI: 10.1007/s10555-007-9088-5. View

20.

Abshire D, Lang M . The Evolution of Radiation Therapy in Treating Cancer. Semin Oncol Nurs. 2018; 34(2):151-157. DOI: 10.1016/j.soncn.2018.03.006. View